Business
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug AdministrationKELOWNA, BC / ACCESSWIRE / April 14, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms announces that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 have been successfully completed with positive safety and efficacy findings.The study findings indicated a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure (\"PASP\") with DehydraTECH-CBD treatment versus placebo. Most notably, PASP was significantly attenuated by about 5 mmHg or 41% overall (p=0.045) in male participants specifically suggesting differences by sex in responsiveness to CBD treatment under hypoxic stress conditions.These findings are complementary to Lexaria's growing body of evidence demonstrating the ability of DehydraTECH-CBD to reduce blood pressure, which it has shown across a wide variety of clinical presentations, ranging from individuals with differing degrees of \"essential hypertension\", the most common form of hypertension, to individuals with stress-induced simulated pulmonary hypertension as reported here. These new findings from HYPER-H21-3 will help direct prospective future research into the efficacy of DehydraTECH-CBD use for the management of elevations in pulmonary arterial pressure under hypoxic conditions (e.g., exposure to altitude), related hypoxemic pathologies (e.g., severe lung disease), and pulmonary hypertension.Lexaria intends to use the data from study HYPER-H21-3, together with the findings from its other previously announced successful studies that evidenced DehydraTECH-CBD's ability to lower human blood pressure, to support Lexaria's plans to seek approvals by the U.S. Food and Drug Administration (\"FDA\") to commence formal, registered clinical testing in the treatment of hypertension under the Investigational New Drug (\"IND\") process.As in past studies, all study participants tolerated DehydraTECH-CBD well and no serious adverse side effects were recorded. Lexaria will continue to provide updates on its work towards...